Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

obesity.knee_.arthritis.jpg

Genes and Obesity Tied to Higher Gout Risk in Women

Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.

Read Article
nobel-prize-1356450__180.jpg

Pain is the Focus of the 2021 Nobel Prize in Medicine

The 2021 Nobel Prize in Medicine and Physiology was jointly awarded to Drs.

Read Article
Telemedicine.MD.Computer.phone (keep)

Telehealth Diet and Exercise Benefits Knee Osteoarthritis

Annals of Internal Medicine has reported the results of a randomized clinical trial showing that telehealth-delivered exercise and diet programs improved pain and function in knee osteoarthritis patients who were overweight.  While both were beneficial, exercise had a greater effect than die

Read Article
FDA.Safety.jpg

FDA Puts Boxed Warnings on JAK Inhibitors

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying a JAK inhibitor. These recommendations apply to tofacitinib, baricitinib and upadacitinib.

Read Article
RheumNow Podcast square

Telemedicine Upside Interview with Dr. Alvin Wells

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for telehealth in rheumatology.

Read Article
dementia,brain

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter study reports that drug hypersensitivity and pulmonary reactions in Still's patients receiving IL-1 or IL-6 inhibitors is strongly associated with HLA-DRB1*15 haplotypes.

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.

Read Article
keystone

RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone

Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.

Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis).

Read Article
×